At the molecular level, LCC and RCC exhibit site‐specific biomarkers, with SETD2 being prognostic for LCC and ARID1A/PRDM1 serving as predictive markers in RCC. This evidence concerns the gene PRDM1 and leukoencephalopathy with calcifications and cysts.